Slide 1: CTIM-76: A Novel CLDN6 x CD3 TCE Phase 1 Interim Results
CTIM-76: A Novel CLDN6 x CD3 TCE Phase 1 Interim Results June 15, 2026
Slide 2: Forward Looking Statement Important Notice and Disclaimers
Executive Summary Forward Looking Statement Important Notice and Disclaimers This presentation contains “forward-looking statements” within the meaning of the Private Securities Certain information contained in this presentation relates to or is based on studies, publications, Litigation Reform Act
Slide 3: On Today's Call
Executive Summary On Today’s Call Pipeline Overview CTIM-76 Development Corporate and Financials Martin Lehr Karen Chagin, MD Jennifer Minai Chief Executive Officer Chief Medical Officer Chief Financial Officer 3 CTIM-76 Phase 1 Interim Results
Slide 4: Introduction
Introduction Martin Lehr CEO, Context Therapeutics 4 CTIM-76 Phase 1 Interim Results
Slide 5: Pipeline Overview
Context Therapeutics Introduction Pipeline Overview ADDRESSABLE MARKET PROGRAM TARGET PRECLINICAL PHASE 1 PHASE 2 ANTICIPATED MILESTONES (U.S. ONLY) Q4 2026: QW updated data CTIM-76 Claudin 6 (CLDN6) > 50,000 patients Q2 2027: Q3W dosing data CT-95 Mesothelin (MSLN) > 100,000 patients Sept 2026: Pre
Slide 6: Context is Positioned to Develop the Next Generation of Transformative T Cell Engagers
Context Therapeutics Introduction Context is Positioned to Develop the Next Generation of Transformative T Cell Engagers Potential to expand into early treatment lines through synergistic drug combinations Optimized Novel Monotherapies Synergistic Combination Approaches CTIM-76 CT-95 CT-202 TCE + AD
Slide 7: Today's Update: Encouraging Phase 1a Clinical Data Observed for CTIM-76
Context Therapeutics Introduction Today’s Update: Encouraging Phase 1a Clinical Data Observed for CTIM-76 CTIM-76 has been granted FDA Fast Track Designation Clinical Activity Low Rate of CRS Pan-PROC Target in Late Line PROC 7 (5-16) prior lines of therapy in PROC 29% confirmed ORR ~75% of platinum
Slide 8: Claudin 6 (CLDN6) Target Overview
Claudin 6 (CLDN6) Target Overview Martin Lehr CEO, Context Therapeutics 8 CTIM-76 Phase 1 Interim Results
Slide 9: CLDN6 is an Attractive Target for Immunotherapy
CTIM-76 Program CLDN6 is an Attractive Target for Immunotherapy CLDN6 is an Ideal TCE Target Avoiding CLDN3 and CLDN4 is a Critical Safety Determinant • CLDN6 is an oncofetal protein. Normally present at higher CLDN9 levels during embryonic development CLDN6 CLDN4 • Turned off or have low levels of
Slide 10: CTIM-76: Claudin 6 x CD3 T cell Engaging (TCE) Bispecific Antibody
CTIM-76 Program CTIM-76: Claudin 6 x CD3 T cell Engaging (TCE) Bispecific Antibody Optimized structure for CLDN6 selectivity, potency, and manufacturability • Highly selective CLDN6 binding fragment antibody-binding (Fab) arm • Immunostimulatory CD3 binding single-chain fragment variable (scFv) doma
Slide 11: CTIM-76 Phase 1 Interim Results
CTIM-76 Phase 1 Interim Results Karen Chagin, MD Chief Medical Officer, Context Therapeutics 11 CTIM-76 Phase 1 Interim Results
Slide 12: CTIM-76 Phase 1a Dose Escalation Trial
CTIM-76 Phase 1 Interim Results CTIM-76 Phase 1a Dose Escalation Trial 2H 2026 QW dose escalation (n=21) evaluating Q3W dosing Target population in ovarian patients Dose 140 560 µg • Ovarian, endometrial and testicular cancer exceeded target exposure Level 5 (n=4) 70 TBD µg relapsed to standard
Slide 13: CTIM-76 Exhibits Compelling Pharmacokinetic (PK) Properties
CTIM-76 Phase 1 Interim Results CTIM-76 Exhibits Compelling Pharmacokinetic (PK) Properties Weekly Dosing (QW) Every Three Week (Q3W) PK Simulation 210 and 280µg doses displayed optimal PK properties, including Cmax Reducing TCE dose frequency has been shown to reduce T cell exhaustion, below target
Slide 14: Patient Demographics at Target Doses of 140 to 280 µg
CTIM-76 Phase 1 Interim Results Patient Demographics at Target Doses of 140 to 280 µg CTIM-76 evaluated in heavily pre-treated patients with high tumor burden Baseline Characteristics All Comers Baseline Characteristics Ovarian N 13 N 9 Age, n (range) 61 (29-72) Age, n (range) 63 (53-74) ECOG, n (ra
Slide 15: Safety Analysis at Target Doses of 140 to 280 µg
CTIM-76 Phase 1 Interim Results Safety Analysis at Target Doses of 140 to 280 µg Observed to be well-tolerated with a favorable safety profile • Adverse events (AE) generally occurred during the first or second dose • Most events were low grade, of short duration, and were reversible with standard m
Slide 16: CRS in PROC Patients at Target Dose Levels
CTIM-76 Phase 1 Interim Results CRS in PROC Patients at Target Dose Levels Benchmarking CRS profiles across approved and experimental TCE Grade 1 Grade 2 Grade 3 60% 50% Low CRS rates may be driven by both programs having tumor restricted targets and utilizing step 40% dosing plus steroid prophylaxi
Slide 17: Interim Phase 1a Data at Target Doses
CTIM-76 Phase 1 Interim Results CTIM-76 Interim Phase 1a Data at Target Doses Tumor reduction combined with manageable CRS profile supports continued clinical development 20% Best Overall % Change in • Dose proportional anti-tumor activity T O O O O Tumor Size From Baseline* • Tumor shrinkage across
Slide 18: Anti-tumor Activity at Target Dose Levels
CTIM-76 Phase 1 Interim Results CTIM-76 Anti-tumor Activity at Target Dose Levels Emerging durability signal, despite weekly dosing during escalation phase Spider Plot 20 Step Dose Cohort All Ovarian 70/140 µg Comers 70/210 µg 0 Patient enrolled, n 13 9 140/280 µg On treatment RECIST evaluable, n 10
Slide 19: Anti-tumor Activity at Target Dose Levels
CTIM-76 Phase 1 Interim Results CTIM-76 Anti-tumor Activity at Target Dose Levels Emerging durability signal with the potential to further improve with less frequent CTIM-76 dosing Months on Treatment Prior Indication Dose 1 2 3 4 5 6 7 8 9 10 11 Rx Testicular 3 280 Ovarian 5 280 Testicular 3 280 Ov
Slide 20: Significant RECIST Response in Ovarian Patient with Liver Lesions
CTIM-76 Phase 1 Interim Results Significant RECIST Response in Ovarian Patient with Liver Lesions Baseline Week 9 Week 16 CA125 3108 ng/mL CA125 272 ng/mL CA125 166 ng/mL 95% Patient Case Study Detail CA125 Decline • PROC patient administered 140µg • 53-year-old female • High disease burden; liver a
Slide 21: T Cell Exhaustion is a Critical Determinant of Tumor Response Durability
CTIM-76 Phase 1 Interim Results T Cell Exhaustion is a Critical Determinant of Tumor Response Durability Q3W dosing may delay T cell exhaustion, improve treatment durability, and be more convenient for patients1 Ovarian Patient @ 70/140 µg Testicular Patient @ 140/280 µg Partial Response Partial Res
Slide 22: Rationale for CTIM-76 in PROC
Rationale for CTIM-76 in PROC Karen Chagin, MD Chief Medical Officer, Context Therapeutics 22 CTIM-76 Phase 1 Interim Results
Slide 23: Significant Market Opportunity in High Unmet Need CLDN6+ Post-ADC PROC
CTIM-76 in Platinum-resistant Ovarian Cancer Significant Market Opportunity in High Unmet Need CLDN6+ Post-ADC PROC • ~75% of PROC patients are CLDN6+ Broad Use Case as Monotherapy or Combination • No approved treatment option specifically for this CTIM-76 CTIM-76 + ADC biomarker selected PROC popul
Slide 24: Patient Population (US Only)
CTIM-76 in Platinum-resistant Ovarian Cancer Patient Population (US Only) 21,010 new cases and 12,450 deaths per year Primary Surgery 1L PLAT + CHEMO ± BEV OTHER 12k 1LM PARP ± BEV BEV 9k Potential to Move Into Earlier Lines PSOC 2L PLAT + CHEMO ± BEV BEV Combo PARP ± CHEMO 10k CTIM-76 ± ADC or Chem
Slide 25: Initial Product Development in Platinum-resistant Ovarian Cancer (PROC)
CTIM-76 in Platinum-resistant Ovarian Cancer Initial Product Development in Platinum-resistant Ovarian Cancer (PROC) CTIM-76 therapeutic window supports broad monotherapy and combination therapy development program in PROC Current Future / Conceptual PROC Treatment Algorithm PROC Treatment Algorithm
Slide 26: Competitive Profile for CTIM-76 in PROC
CTIM-76 in Platinum-resistant Ovarian Cancer Competitive Profile for CTIM-76 in PROC Encouraging tumor response and safety profile in heavily pretreated / ADC-experienced patient population CTIM-76 Multiple Nab-Paclitaxel Azenosertib Brenetafusp Target CLDN6 CDH6, FRα, NaPi2b Microtubule Wee1 PRAME
Slide 27: Concluding Remarks
Concluding Remarks 27 CT IM- 76 Phas e 1 Inter im Res ults
Slide 28: Anticipated Key Milestones in 2026-2027
Concluding Remarks Anticipated Key Milestones in 2026-2027 • Multiple data inflection points over the next 12 months • Current cash runway into mid-2027 PROGRAM 1H 2026 2H 2026 1H 2027 2H 2027 target CTIM-76 Ph 1a Ph 1a Ph 1b Claudin 6 (CLDN6) Dose Escalation Q3W Dose Evaluation Dose Expansion CT-95
Slide 29: CTIM-76 Phase 1a Interim Data Summary and Next Steps
Concluding Remarks CTIM-76 Phase 1a Interim Data Summary and Next Steps Clinical activity demonstrated for CLDN6 x CD3 TCE Potential best-in-class CLDN6 TCE could present a multi-billion dollar opportunity Evaluating Q3W dosing to potentially enhance patient convenience and combinability Promising s
Slide 30: Advancing T Cell Engagers for Solid Tumors
context therapeutics Advancing T Cell Engagers for Solid Tumors c o©nCONTEXT text THERAPEUTICS 2026 CTIM- 76 Phase 1 Interim R esults 30
Slide 31: Glossary
Appendix Glossary ADC Antibody drug conjugate MTD Maximum tolerated dose AE Adverse event N.D. Not disclosed CAR-T Chimeric antigen receptor T cell therapy ORR Overall response rate CD3 Cluster of differentiation 3 PFS Progression free survival CLDN Claudin PK Pharmacokinetic CRS Cytokine release sy